放疗联合唑来膦酸治疗乳腺癌骨转移76例疗效分析  

Effect of radiotherapy combined with zoledronic acid in the treatment of 76 cases of breast cancer with bone metastases

作　　者：卢月[1] 汪成[2] 陈刚[1] 张顺康[1] LU Yue;WANG Cheng;CHEN Gang;ZHANG Shunkang(the Central Hospital of Huangpu District,Shanghai 200002,China;Department of Breast Surgery)

机构地区：[1]上海市黄浦区中心医院放疗科,上海200002 [2]上海市黄浦区中心医院乳腺外科,上海200002

出　　处：《上海医药》2019年第5期21-24,共4页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的 :评估放疗联合唑来膦酸治疗乳腺癌骨转移的临床疗效。方法 :选取76例乳腺癌骨转移患者,随机分为A组(放疗联合唑来膦酸组,35例)和B组(单纯放疗组,41例),比较放疗结束及3个月时两组的疗效,并随访1年观察两组的骨相关事件发生率和其它不良反应发生情况。结果 :A组骨痛缓解率明显优于B组;随访1年骨相关事件发生率显著低于B组(P <0.05)。两组不良反应发生率无明显差异(P> 0.05)。结论 :放疗联合唑来膦酸治疗乳腺癌骨转移与单纯放疗相比,疼痛缓解率高,并能显著减少骨相关事件发生率,且不良反应发生率无明显差异。Objective:To evaluate the clinical efficacy of radiotherapy combined with zoledronic acid in the treatment of breast cancer with bone metastases.Methods:Seventy-six patients with breast cancer and bone metastases were selected and randomly divided into group A(35 cases,treated with radiotherapy combined zoledronic acid)and B(41 cases,treated with radiotherapy alone).The efficacy was compared between the two groups at the end of radiotherapy and 3 months after radiotherapy,and the incidence of bone-related events and the occurrence of adverse reactions in the two groups were observed within one year follow-up.Results:The rate of bone pain relief was significantly better and the incidence of bone-related events was significantly lower in group A than group B(P<0.05).There were no significant differences between the two groups in the incidence of adverse reactions(P>0.05).Conclusion:As compared with radiotherapy alone,the combination of radiotherapy with zoledronic acid for the treatment of breast cancer with bone metastases has higher rate of pain relief and lower incidence of adverse reactions without significant differences in adverse reactions.

关 键 词：乳腺癌 骨转移 放疗 唑来膦酸 

分 类 号：R979.19[医药卫生—药品] R738.1[医药卫生—药学]